Share this article
Share this article
REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study with University Hospitals (UH) Cleveland Medical Center that will evaluate the postoperative use of DSUVIA in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol. Dr. Daniel Asher, cardiac anesthesiologist and Medical Director of the Mather Postanesthesia Care Unit at UH Cleveland Medical Center, will serve as the principal investigator. Key outcomes to be measured include time on mechanical ventilation following completion of the surgical procedure, both intensive care as well as hospital length of stay and total dose of opioids administered from surgery to disc
E-Mail
CLEVELAND - In a new paper, researchers describe their development of a near-real time spatial assessment of COVID-19 cases to help guide local medical responses to clusters of outbreaks of the virus at the local level.
The paper, entitled Geographic monitoring for early disease detection (GeoMEDD), appeared in the Dec. 10 issue of Nature
Scientific Reports and comes from researchers at Case Western Reserve University (CWRU) School of Medicine, University Hospitals (UH) Cleveland Medical Center, and Texas A & M University.
While developing a tracking system during the beginning stages of the COVID-19 pandemic, the authors realized that there was a need to refocus more traditional spatial mapping towards a more granular cluster detection methodology that provides syndromic surveillance, or early indicators of emergent disease by leveraging a health system s access to data streams from various sources which account for location and timing of cases.